ClinicalTrials.gg
RecruitingNCT02107105Updated Aug 31, 2026

Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer

An observational study in Rectal Adenocarcinoma, Stage I Rectal Cancer AJCC v8 and Stage II Rectal Cancer AJCC v8, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by M.D. Anderson Cancer Center · Observational

How we know

From the registry’s dates

  • Started May 2014; still recruiting 12 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
430
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Rectal Neoplasms by M.D. Anderson Cancer Center — 3 open to participants now, 10 under way, none of them phase 3. Rectal Neoplasms · M.D. Anderson Cancer Center.

Started
2014
the only one that year
Observational
5 of 27
1 open now
Registered
15th of 27
by date

Among the 27 studies in Rectal Neoplasms by M.D. Anderson Cancer Center, this one is the only one that started in 2014, is one of 5 observational ones, and was the 15th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

3 of the 27 studies in Rectal Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Rectal Neoplasms by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

This study evaluates quality of life and utilities following surgical treatment of stage I-IV rectal cancer. This study may help researches learn more about quality of life in patients who have or have had rectal cancer.

Read the detailed description

PRIMARY OBJECTIVE:

I. To assess post-treatment related health state utilities among patients with rectal cancer after treatment at 2 years.

SECONDARY OBJECTIVES:

I. To longitudinally compare the effects of treatment on quality of life and utilities among patients treated with or without (neo)adjuvant radiation therapy.

II. To characterize the impact of treatment on quality of life and utilities among patients with rectal cancer.

III. To assess changes in quality of life and utilities among patients treated for rectal cancer over time.

IV. To identify gaps in preoperative counseling for pelvic exenteration by eliciting in-depth insights into patient values, expectations, and lived experiences through qualitative interviews with patients who have undergone surgery for locally advanced or recurrent rectal cancer.

V. To identify themes, communication strategies, and informational content used during preoperative counseling for pelvic exenteration through qualitative interviews with providers.

OUTLINE:

Patients complete quality of life questionnaires over 20-30 minutes at baseline, 6 and 12 months after surgery, and 2, 3, 4, and 5 years after surgery.

03

Conditions studied

  • Rectal Adenocarcinoma
  • Stage I Rectal Cancer AJCC v8
  • Stage II Rectal Cancer AJCC v8
  • Stage IIA Rectal Cancer AJCC v8
  • Stage IIB Rectal Cancer AJCC v8
  • Stage IIC Rectal Cancer AJCC v8
  • Stage III Rectal Cancer AJCC v8
  • Stage IIIA Rectal Cancer AJCC v8
  • Stage IIIB Rectal Cancer AJCC v8
  • Stage IIIC Rectal Cancer AJCC v8
  • Stage IV Rectal Cancer AJCC v8
  • Stage IVA Rectal Cancer AJCC v8
  • Stage IVB Rectal Cancer AJCC v8
  • Stage IVC Rectal Cancer AJCC v8

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient with stave I-IV rectal adenocarcinoma at the Colorectal Clinic at M D Anderson Cancer Center

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has proven adenocarcinoma of the rectum (stage I - IV) that is planned to be treated by surgical resection performed with curative intent, or who has already received surgical treatment
  • Patient must sign an approved document and have the literary and physical ability to complete the questionnaire in English

Exclusion criteria

Exclusion Criteria:

  • Patient has been treated with pelvic radiation therapy for a diagnosis other than rectal cancer
  • Patient has a concurrent cancer diagnosis at the time of consent
  • Patient has recurrent disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
430 participants (estimated)
Patient registry
No

Groups and cohorts

  • Observational (questionnaire)

    Patients complete quality of life questionnaires over 20-30 minutes at baseline, 6 and 12 months after surgery, and 2, 3, 4, and 5 years after surgery.

    Other: Quality-of-Life Assessment · Other: Questionnaire Administration

Interventions

  • OtherQuality-of-Life Assessment

    Complete quality of life questionnaire

    Also known as: Quality of Life Assessment

  • OtherQuestionnaire Administration

    Complete quality of life questionnaire

06

What researchers measure

Primary outcomes

  1. Health state utilities

    A health state utility is the degree of preference that individuals or society has for a particular health state or condition.

    Time frame: At 24 months post-surgery

07

Study locations

1 of 1 sites recruiting
  • M D Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • George J. Chang · Contact713-792-6940
    • George J. Chang · Principal investigator
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2014 (actual). Primary completion is estimated for May 2030, 192 months after the start.

Of 214 non-industry observational studies under Rectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 118. This study's planned 192 months is above that.

Counting every sponsor, half of 229 studies reached it within 45 months; a quarter within 24 and three quarters within 116.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2014
First posted
Apr 8, 2014
StartActual
May 16, 2014
Primary completionEst.
May 31, 2030
CompletionEst.
May 31, 2030
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02107105
Responsible party
Sponsor
First posted
Apr 8, 2014
Start date
May 16, 2014
Primary completion
May 31, 2030 (estimated)
Completion
May 31, 2030 (estimated)
Last update
Aug 31, 2026

Study contacts

George Chang
Contact
GChang@mdanderson.org
713-792-6940
George J Chang
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion